NCT00039858已完成4 期
Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 26
研究概览
简要总结
The purpose of this study is to evaluate the safe and effective dose of Argatroban for prophylaxis and/or treatment of thrombosis in pediatric patients with current or previous diagnosis of heparin-induced thrombocytopenia (HIT) and thrombosis syndrome (HITTS), or who in the opinion of the investigator require alternative anticoagulation due to an underlying condition.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- — 至 16 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (26)
Loading locations...
相似试验
已完成
1 期
Argatroban Stroke Treatment - A Pilot Safety StudyIschemic StrokeNCT00268762The University of Texas Health Science Center, Houston65
已完成
4 期
Pharmacokinetics/Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease Patients Undergoing HemodialysisRenal Disease, End-StageKidney Failure, ChronicNCT00035178Texas Biotechnology Corporation12
已完成
4 期
Argatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery StentingCVDNCT01163604Jinling Hospital, China114
招募中
2 期
Avatrombopag in the Treatment of Pediatric Immune ThrombocytopeniaTreatmentImmune ThrombocytopeniaNCT06281327Institute of Hematology & Blood Diseases Hospital, China60
已完成
3 期
Hetrombopag for Pediatric Patients With Chronic Immune ThrombocytopeniaImmune ThrombocytopeniaNCT04737850Jiangsu HengRui Medicine Co., Ltd.100